Pharmaceutical Industry in
Schlieren
41 companies in Pharmaceutical Industry based in Schlieren — name and year of registration from the commercial register. The list below shows them all.
All 41 companies in Schlieren
Molecular Partners AG
Since 2004 · 101–500 empl.4.9(11)
The company develops innovative therapeutic compounds, in particular DARPins, for diseases with high unmet medical need, with a focus on ophthalmology and oncology.
LimmaTech Biologics AG
Since 2015 · 51–100 empl.4.8(4)
The core activity of LimmaTech Biologics AG is the development and manufacture of vaccines and other biotechnological products, particularly in the field of infectious diseases. The company focuses on the development of a proprietary vaccine platform and has a pipeline of products in various stages of development.
Mabylon AG
Since 2011 · 11–20 empl.4.7(3)
The core activity of Mabylon AG is research and development in the field of biotechnology.
InterAx Biotech AG
Since 2016 · 11–20 empl.5.0(2)
The core activity of InterAx Biotech AG is the development of solutions in the field of computer-aided chemistry and systems biology, particularly in the context of GPCR signaling pathways and medicinal chemistry. The company combines expertise in computer science, biology, chemistry, and pharmacy to develop innovative approaches for the development of drugs and therapies.
Roche Glycart AG
Since 2000 · 11–20 empl.
Roche Glycart AG is part of Roche and is engaged in pharmaceutical and diagnostic solutions. The company focuses on medicines, diagnostics, digital products, and related services across the patient journey.
CONARTIX GmbH
Since 2006 · 1–10 empl.
The core activity of Conartix Health AG is the development, manufacture and marketing of nature-based health products and dietary supplements, particularly based on plant-based substances and prebiotics, with the aim of promoting human health and quality of life.
Redbiotec AG
Since 2006 · 11–20 empl.
The core activity of Redbiotec AG is the development and production of key proteins and genetic materials for the biopharmaceutical and food industries. The company focuses on the research and development of therapeutic bacteria for the treatment of cancer and genetic diseases.
Virometix AG
Since 2009 · 11–20 empl.
The core activity of Virometix AG is the development of pharmaceuticals and therapeutics, particularly in the fields of oncology and virology, using live biotherapeutics and other innovative technologies.
Axanton Technology GmbH
Since 2013 · 1–10 empl.
Axanton Technology GmbH develops MEMS (Molecules Establishing Membrane Signaling), a technology for producing therapeutic biomolecules that target chemically modified membrane protein sequences to restore membrane protein homeostasis. The company conducts research and preclinical development of candidates such as A‑144 and holds patented technology for MEMS production.
Swiss Bioscience GmbH
Since 2014 · 11–20 empl.
The core activity of Swiss Bioscience GmbH is the development and production of pharmaceutical-grade stem cells, particularly human adipose tissue-derived stem cells (hADSCs), under cGMP conditions. The company offers services such as stem cell banking, research and development, and focuses on the application of stem cells in regenerative medicine, particularly for the treatment of age-related diseases.
NovaGo Therapeutics AG
Since 2015 · 11–20 empl.
The core activity of Neurimmune (or NovaGo) is the development of therapeutic antibodies for the treatment of neurodegenerative and other diseases, particularly Alzheimer's, Parkinson's, tauopathies, and amyotrophic lateral sclerosis. The company focuses on the discovery, development, and clinical testing of antibody-based medications.
Cellerys AG
Since 2015 · 11–20 empl.
The core activity of Cellerys AG is the development of therapies for the treatment of autoimmune diseases, particularly multiple sclerosis, through the application of immunotherapies and cell therapies. The company focuses on the development of EpiTCer-based therapies, which aim to modulate the immune response to autoreactive T-cells. Cellerys conducts clinical trials and collaborates with partners such as Novartis and TETEC to develop and market its therapies.
Repertoire Immune Medicines (Switzerland) AG
Since 2018 · 21–50 empl.
The core activity of Repertoire Immune Medicines is the development of innovative immunotherapies for various therapeutic areas, particularly for cancer, autoimmune diseases, and infectious diseases. The company utilizes its proprietary DECODE platform to decipher the unique immune codes of the human body and develop medicines that can program the immune system to selectively eliminate tumors or restore balance to the immune system in autoimmune diseases.
Memo Therapeutics AG
Since 2019 · 21–50 empl.
Memo Therapeutics AG develops therapeutic antibodies based on natural immune responses, with a focus on viral infections and cancer. Its main program is potravitug for BK polyomavirus infection in kidney transplant recipients, supported by the DROPZYLLA® platform for antibody discovery.
Athebio AG
Since 2019 · 21–50 empl.
The core activity of Athebio AG is the development and provision of proprietary technology for the creation of targeted therapeutics with improved efficacy and safety, particularly through the use of "plug & play" DARPin technology (Athebody). The company focuses on partnering with pharmaceutical companies to develop and market innovative medicines.
SIEGFRIED DiNAMIQS AG
Since 2020 · 21–50 empl.
SIEGFRIED DiNAMIQS AG is a CDMO for advanced medicine providing GMP‑compatible manufacturing and scalable production of viral vectors. The company focuses on AAV manufacturing and development for viral therapeutics and originated as a spin‑out from DiNAQOR before being scaled through a majority‑stake transaction with Siegfried.
BiognoSYS AG
Since 2008 · 51–100 empl.5.0(1)
The core activity of Biognosys is the development and provision of technologies and services in the field of proteomics, particularly in the areas of large-scale proteomics, biomarker discovery and analysis. The company offers software, kits and contract research services to support customers in life science research and drug development.
DISCO Pharmaceuticals Swiss GmbH
Since 2023 · 21–50 empl.
DISCO Pharmaceuticals Swiss GmbH applies a surfaceome mapping platform to identify cell-surface proteins and protein communities, providing molecular targets for antibody-based cancer therapies. Its initial discovery programs focus on small cell lung cancer and microsatellite-stable colorectal cancer, supporting candidate generation for mono- and bispecific antibodies and antibody–drug conjugates.
CUTISS AG
Since 2017 · 21–50 empl.5.0(2)
The core activity of CUTISS is the development and application of technologies in regenerative medicine, particularly in the field of skin tissue therapy, regenerative medicine, tissue engineering and skin pigmentation. The company focuses on the development of personalized tissue therapies to revolutionize skin surgery and dermatology.
Polaroid Therapeutics AG
Since 2023 · 1–10 empl.
Polaroid Therapeutics AG develops proprietary technologies to reduce bioburden and support antimicrobial therapies. Its activities focus on wound management products, long‑lasting medical‑device coatings and therapeutic applications employing methods such as 3D printing, artificial intelligence and advanced delivery systems.
Topadur Pharma AG
Since 2015 · 11–20 empl.5.0(2)
The core activity of Topadur Pharma AG is the development and research of drugs and therapies, particularly in the field of regenerative medicine, medical aesthetics, oncology, ophthalmology and fibrosis. The company focuses on topical local administration of substances to achieve an optimal combination of efficacy and safety.
HeiQ GrapheneX AG
Since 2019 · 51–100 empl.2.6(5)
HeiQ GrapheneX AG develops porous graphene materials synthesized directly via a scalable Chemical Vapor Deposition (CVD) process. The materials combine atomically thin, high‑strength and conductive graphene with engineered porosity and are intended for membrane applications such as water filtration, electronic vents and lithium‑metal battery electrodes.
Tandem Therapeutics AG
Since 2023 · 1–10 empl.
The core activity of Tandem Therapeutics AG is the development of transformative medicines that focus on the extracellular matrix, particularly for the treatment of fibrotic diseases and fibrotic cancer forms. The company uses Matrix-Targeting-Peptides (MTP) that conditionally target disease-associated matrix changes to overcome the extracellular matrix barrier and enable new therapeutic approaches.
AeoniQ Holding AG
Since 2023 · 101–500 empl.2.6(5)
AeoniQ Holding AG offers the AeoniQ™ technology, a climate-positive continuous cellulosic filament yarn intended to replace polyester and nylon in textile applications.
Proxima Bio GmbH
Since 2026 · 21–50 empl.
Proxima Bio GmbH develops AI-based platforms for drug discovery and the analysis of protein interactions. The company focuses on structure prediction, molecular design, and data platforms for proximity-modulation therapeutics.
Baxiva AG
Since 2025 · 1–10 empl.
Baxiva AG develops glycoconjugate vaccines for the prevention of bacterial infections. Its platform chemically links serotype-specific bacterial polysaccharides to virus-like particles (VLPs) to generate immunogenic, multivalent vaccine candidates against Gram-negative pathogens such as Escherichia coli.
DAiNA Laboratories AG
Since 2025 · 1–10 empl.
DAiNA Laboratories AG develops approaches for personalized cancer care. The company combines AI with molecular data and biological analyses to characterize tumors individually and support treatment decisions.
ALP Bio AG
Since 2026 · 1–10 empl.
ALP Bio AG develops a platform for immunogenicity analysis in biologics development. The company combines human tonsil organoid technology with AI-based protein analysis to assess and reduce anti-drug antibody risk in therapeutic antibodies earlier in development.
SuissTech Engineering AG
Since 2011 · 1–10 empl.
SuissTech Engineering AG is a subsidiary of Omnimedica AG that develops and supplies decontamination agents such as Clinocarbonit®, used to bind and remove radioactive particles (e.g., iodine and cesium) from drinking water and food.
Celland AG
Since 2026 · 1–10 empl.
Celland AG offers oral supplements based on stem cell research and cell-related signaling molecules. The company presents its products as part of a cGMP-oriented manufacturing approach in regenerative medicine and cellular vitality.
Adugen AG
Since 2015 · 1–10 empl.
AL-S Pharma AG
Since 2016 · 1–10 empl.
SURI BioTech GmbH
Since 2023 · 1–10 empl.
OmnilinX Therapeutics AG
Since 2023 · 1–10 empl.
DiNABIOS AG
Since 2023 · 1–10 empl.
Vivtex GmbH
Since 2023 · 1–10 empl.
SYDRA AG
Since 2024 · 1–10 empl.
syntelios AG
Since 2024 · 1–10 empl.
Elixion BioTech AG
Since 2025 · 1–10 empl.
Livality AG
Since 2025 · 1–10 empl.
OphthaNova Therapeutics AG
Since 2025 · 1–10 empl.
Pharmaceutical Industry in Schlieren
Pharmaceutical Industry in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Pharmaceutical Industry in other places
By canton